LUBRANO DI SCORPANIELLO, Ennio
 Distribuzione geografica
Continente #
NA - Nord America 12.089
EU - Europa 10.048
AS - Asia 2.737
SA - Sud America 1.020
AF - Africa 474
OC - Oceania 26
Continente sconosciuto - Info sul continente non disponibili 15
Totale 26.409
Nazione #
US - Stati Uniti d'America 11.891
RU - Federazione Russa 4.628
IE - Irlanda 1.958
SG - Singapore 1.200
BR - Brasile 834
CN - Cina 609
UA - Ucraina 544
IT - Italia 537
FI - Finlandia 457
AT - Austria 374
DE - Germania 373
CI - Costa d'Avorio 354
SE - Svezia 332
GB - Regno Unito 304
FR - Francia 283
VN - Vietnam 268
HK - Hong Kong 148
CA - Canada 116
IN - India 104
AR - Argentina 73
BD - Bangladesh 57
MX - Messico 50
NL - Olanda 50
JP - Giappone 46
ZA - Sudafrica 45
TR - Turchia 42
BE - Belgio 39
IQ - Iraq 39
ES - Italia 33
ID - Indonesia 32
PL - Polonia 31
CO - Colombia 30
EC - Ecuador 26
LT - Lituania 26
AU - Australia 20
IR - Iran 19
MA - Marocco 17
SA - Arabia Saudita 17
IL - Israele 16
PK - Pakistan 16
CL - Cile 15
KZ - Kazakistan 15
EU - Europa 14
KR - Corea 14
JO - Giordania 13
VE - Venezuela 13
EG - Egitto 12
AZ - Azerbaigian 11
RO - Romania 10
AE - Emirati Arabi Uniti 9
CZ - Repubblica Ceca 9
HR - Croazia 9
TN - Tunisia 9
JM - Giamaica 8
KE - Kenya 8
MY - Malesia 8
PE - Perù 8
UY - Uruguay 8
PY - Paraguay 7
TT - Trinidad e Tobago 7
UZ - Uzbekistan 7
BO - Bolivia 6
CH - Svizzera 6
GR - Grecia 6
PA - Panama 6
PT - Portogallo 6
SN - Senegal 6
AL - Albania 5
BG - Bulgaria 5
DZ - Algeria 5
KG - Kirghizistan 5
LV - Lettonia 5
NP - Nepal 5
NZ - Nuova Zelanda 5
PH - Filippine 5
DO - Repubblica Dominicana 4
ET - Etiopia 4
GE - Georgia 4
LK - Sri Lanka 4
TH - Thailandia 4
BY - Bielorussia 3
DK - Danimarca 3
LB - Libano 3
NO - Norvegia 3
OM - Oman 3
PS - Palestinian Territory 3
SK - Slovacchia (Repubblica Slovacca) 3
AO - Angola 2
CY - Cipro 2
GI - Gibilterra 2
KW - Kuwait 2
NG - Nigeria 2
NI - Nicaragua 2
TW - Taiwan 2
YT - Mayotte 2
BB - Barbados 1
BW - Botswana 1
CD - Congo 1
CG - Congo 1
CM - Camerun 1
Totale 26.390
Città #
Dallas 4.370
Dublin 1.958
Moscow 1.531
Jacksonville 1.322
Chandler 1.133
Singapore 601
Wilmington 409
Vienna 366
Abidjan 354
Helsinki 313
Ashburn 307
Rome 274
Houston 260
San Mateo 248
The Dalles 241
Beijing 205
Ann Arbor 185
Princeton 179
Los Angeles 161
Hong Kong 147
Boardman 146
Woodbridge 146
Columbus 106
New York 100
Ho Chi Minh City 99
Dearborn 94
São Paulo 84
Hanoi 47
Council Bluffs 45
Tokyo 42
Redwood City 41
Chicago 37
Brooklyn 36
London 36
Mountain View 36
Santa Clara 36
Brussels 35
Amsterdam 34
Molise 34
Toronto 34
Johannesburg 33
Montreal 32
Rio de Janeiro 31
San Francisco 30
Denver 29
Frankfurt am Main 27
Jinan 27
Atlanta 26
Warsaw 25
Manchester 22
Orem 22
Mexico City 20
Milan 20
Nuremberg 20
Seattle 20
Boston 19
Chennai 19
Nanjing 19
Shenyang 18
Falls Church 17
Guangzhou 17
Phoenix 17
Dhaka 16
Shanghai 16
Ottawa 15
Augusta 14
Ningbo 14
Auburn Hills 13
Leawood 13
Stockholm 13
Amman 12
Belo Horizonte 12
Haikou 12
Jakarta 12
Porto Alegre 12
Baghdad 11
Brasília 11
Falkenstein 11
Fortaleza 11
Zhengzhou 11
Ardabil 10
Assago 10
Baku 10
Bogotá 10
Dong Ket 10
Poplar 10
Borås 9
Charlotte 9
Haiphong 9
Hải Dương 9
Istanbul 9
Ninh Bình 9
Norwalk 9
Paris 9
Pittsburgh 9
Rockville 9
St Louis 9
Taizhou 9
Campinas 8
Changsha 8
Totale 16.755
Nome #
A 12-point recommendation framework to support advancement of the multidisciplinary care of psoriatic arthritis: A call to action 2.687
An ultrasonographic study of enthesis in early psoriatic arthritis patients naive to traditional and biologic DMARDs treatment 225
An overview of low disease activity and remission in psoriatic arthritis. 186
An Assessment of Hand Erosive Osteoarthritis: Correlation of Radiographic Severity with Clinical, Functional and Laboratory Findings 186
Analysis of potential determinants for a treat-to-target strategy in psoriatic arthritis patients from a real-world setting 183
Assessment of response to treatment, remission, and minimal disease activity in axial psoriatic arthritis treated with tumor necrosis factor inhibitors 181
An audit of anthropometric measurements by medical and physiotherapy staff in patients with ankylosing spondylitis 174
ANTHROPOMETRIC MEASUREMENTS AND DISABILITY IN A OPEN FOLLOW UP STUDY ON ANKYLOSING SPONDYLITIS WITH COMBINED MEDICAL AND REHABILITATIVE TREATMENT 166
Assessment of subclinical atherosclerosis in ankylosing spondylitis: Correlations with disease activity indices 165
Aortic involvement in ankylosing spondylitis 163
Antiphospholipid syndrome, activated protein C resistance and mutation C -> T 677 in the MTHFR gene with juvenile pulmonary embolism. A case report 163
Assessment of bone morphogenic protein 2 and interleukine-17A in patients with axial spondyloarthritis and their potential role in the new bone formation: a cross-sectional study 163
Beyond TNF Inhibitors: New Pathways and Emerging Treatments for Psoriatic Arthritis 162
A novel biological target for the treatment of psoriatic arthritis. 161
Assessment of semaphorin 3A and its role in bone remodelling in a group of ankylosing spondylitis patients 161
Chronic periaortitis with retroperitoneal fibrosis successfully treated with first line tocilizumab monotherapy: a case report 160
Beyond the joint: Subclinical atherosclerosis in rheumatoid arthritis 158
Assessment of the Patient Acceptable Symptom State (PASS) in psoriatic arthritis: Association with disease activity and quality of life indices 156
From clinical remission to residual disease activity in spondyloarthritis and its potential treatment implications 154
Remission in ankylosing spondylitis treated with anti-TNF-α drugs: a national multicentre study. 148
Measuring psoriatic disease in clinical practice. An expert opinion position paper. 146
La spondilodiscite delle spondiloartriti sieronegative 146
Validity and reliability of an Italian version of the revised Leeds disability questionnaire for patients with ankylosing spondylitis 145
Assessment of psoriatic nail disease activity by rheumatologists 145
A rare enthesopathy in psoriatic oligoarthritis 145
Cardiovascular Risk Prediction in Ankylosing Spondylitis: From Traditional Scores to Machine Learning Assessment 144
A national survey on the management of psoriatic arthritis using the Delphi method 143
Iperuricemia e rischio cardio-renale 139
Venous thrombophilia in a patient with protein S deficiency, factor V Leiden and homozygous MTHFR C -> T677 mutation 137
The arthritis of coeliac disease: prevalence and pattern in 200 adult patients 136
Sustained Very Low Disease Activity and Remission in Psoriatic Arthritis Patients 136
Incidence of rheumatoid arthritis, psoriatic arthritis and polymyalgia rheumatica in an inland area of central Italy: results of the CAMPO-RHE study 135
Pharmacoeconomic issues in psoriatic arthritis 134
Assessment of widespread and extra-articular pain in psoriatic arthritis: a case-control study 134
Supervised training and home-based rehabilitation in patients with stabilized ankylosing spondylitis on TNF inhibitor treatment: a controlled clinical trial with a 12-month follow-up 133
Validity, responsiveness and feasibility of an Italian version of the Canadian Occupational Performance Measure for patients with ankylosing spondylitis 133
Switching from infliximab or etanercept to adalimumab in resistant or intolerant patients with spondyloarthritis: a 4-year study 131
Unmet needs in outcome measures of Psoriatic Arthritis: focus on axial radiographic and nail involvement 130
Impact of Comorbidities on Disease Activity, Patient Global Assessment, and Function in Psoriatic Arthritis: A Cross-Sectional Study 130
The arthritis of ulcerative colitis: clinical and genetic aspects 128
Simple clinical indicators for early psoriatic arthritis detection. 127
Subcutaneous anti-TNF alfa induced sustained minimal disease activity and remission in psoriatic arthritis patients: a retrospective study 127
Is the Nail Psoriasis Severity Index reliable in the assessment of nail psoriasis by rheumatologists? 126
Can traditional disease-modifying anti-rheumatic drugs be withdrawn or tapered in psoriatic arthritis? 126
The role of IL-17 in the treatment of psoriatic arthritis 126
Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs -- comparison of drugs and adverse reactions 125
Mesenchimal stem cells: A possible role in the pathogenesis and treatment of spondyloarthritis 125
Pharmacoeconomic burden in the treatment of psoriatic arthritis: from systematic reviews to real clinical practice studies 125
Patient education in psoriatic arthritis: a cross sectional study on knowledge by a validated self-administered questionnaire 124
The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy 123
Residual disease activity in rheumatoid arthritis patients treated with subcutaneous biologic drugs that achieved remission or low disease activity: a longitudinal observational study 122
Consensus on the management of patients with psoriatic arthritis in a dermatology setting 122
Patient's global assessment as an outcome measure for psoriatic arthritis in clinical practice: A surrogate for measuring low disease activity? 121
The assessment of knowledge in ankylosing spondylitis patients by a self-administered questionnaire 119
Comparison of composite indices tailored for psoriatic arthritis treated with csDMARD and bDMARD: A cross-sectional analysis of a longitudinal cohort 119
The performance of CASPAR criteria in early psoriatic arthritis - preliminary results from an Italian prospective multicentric study 118
Secukinumab for ankylosing spondylitis and psoriatic arthritis 118
The effectiveness of a biologic agent on axial manifestations of psoriatic arthritis. A twelve months observational study in a group of patients treated with etanercept 118
Trauma and seronegative spondylarthropathy 117
Joint symmetry in early and late rheumatoid and psoriatic arthritis: comparison with a mathematical model 117
Venous thrombophilia with severe mesenteric involvement associated to homozygosity for factor V Leiden and heterozygosity for G20210A mutation of prothrombin 117
Latent tuberculosis infection detection and active tuberculosis prevention in patients receiving anti-TNF therapy: an Italian nationwide survey. 117
Tumour necrosis factor alpha inhibitor therapy and rehabilitation for the treatment of ankylosing spondylitis: A systematic review. 117
Validation of the Italian version of proposed GRAPPA flare questionnaire for patients with psoriatic arthritis 117
Somatic perception in irritable bowel syndrome (IBS) patients with and without fibromyalgia (FMS). Does the severity of IBS influence the perception of somatic stimuli? 116
Minimal Disease Activity and Remission in Psoriatic Arthritis Patients Treated with Anti-TNF-α Drugs 116
Multidisciplinary Management of Spondyloarthritis-Related Immune-Mediated Inflammatory Disease 116
The adherence to ASAS classification criteria and to ASAS recommendations for the use of anti-TNH-alpha agents in axial spondyloarthritis. 115
Predictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNFα drugs 115
Axonal degeneration in systemic sclerosis can be reverted by factors improving tissue oxygenation 115
Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study 115
LA COMPLICANZA ARTICOLARE DELLA MALATTIA CELIACA. STUDIO SU 62 CASI: RISULTATI PRELIMINARI 115
Unmet Needs in Axial Spondyloarthritis 115
Role of comorbidities in spondyloarthritis including psoriatic arthritis 115
Etanercept in psoriatic arthritis 115
Profile of ustekinumab and its potential in the treatment of active psoriatic arthritis 114
Treatment options: NSAIDs and DMARDs 114
Remission in nonradiographic axial spondyloarthritis treated with anti-tumor necrosis factor-α drugs: an Italian multicenter study. 114
Updated guidelines for the management of axial disease in psoriatic arthritis 114
An International Multidisciplinary Delphi-Based Consensus on Heat Therapy in Musculoskeletal Pain 113
Cardiovascular comorbidities in psoriatic arthritis: epidemiology and risk factors in two different European populations 113
Subcorneal pustular dermatosis (Sneddon-Wilkinson syndrome): another cutaneous manifestation of SAPHO syndrome? 113
Defining low disease activity states in psoriatic arthritis using novel composite disease instruments 113
Predictors of loss of remission and disease flares in patients with axial spondyloarthritis receiving antitumor necrosis factor treatment: A retrospective study 113
Multimorbidity and comorbidity in psoriatic arthritis–a perspective 113
Management of psoriatic arthritis in rheumatology and dermatology settings: sub-analysis of the Italian population from the international LOOP study 113
Physical trauma triggers psoriasis in a patient with undifferentiated seronegative spondyloarthropathy 112
Validity of the modified stoke ankylosing spondylitis spine score (M-SASSS) and of the bath ankylosing spondylitis radiology index (BASRI) for the radiological assessment of axial involvement in psoriatic arthritis. multicentre validation study. Part one. 112
The effectiveness of rehabilitation in active ankylosing spondylitis assessed by the ASAS response criteria 112
Elderly psoriatic arthritis patients on TNF-α blockers: results of an Italian multicenter study on minimal disease activity and drug discontinuation rate 112
Recommendations for the use of biologic therapy in the treatment of psoriatic arthritis: update from the Italian Society for Rheumatology 111
Current evidence in the field of the management with TNF-α inhibitors in psoriatic arthritis and concomitant hepatitis C virus infection. 110
Assessment of Patient-Physician Interactions in Psoriatic Arthritis: National Results of the ASSIST Study 109
Qualifying Unmet Needs and Improving Standards of Care in Psoriatic Arthritis. 109
The radiological assessment of axial involvement in psoriatic arthritis: a validation study of the BASRI total and the modified SASSS scoring methods. 109
Current approach to the management of psoriatic arthritis according to a sample of Italian rheumatologists 108
An international multi-centre analysis of current prescribing practices and shared decision-making in psoriatic arthritis 107
Long-term costs and outcomes in psoriatic arthritis patients not responding to conventional therapy treated with tumour necrosis factor inhibitors: An extension of the Psoriatic Arthritis Cost Evaluation (PACE) study 107
Dactylitis and Early Onset Psoriasis in Psoriatic Arthritis: Are they Markers of Disease Severity? A Clinical Study 105
Psoriatic disease: Clinical staging 105
Totale 15.608
Categoria #
all - tutte 119.104
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 119.104


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021861 0 0 0 0 0 102 199 20 206 17 266 51
2021/2022968 51 252 16 31 55 28 29 106 141 154 43 62
2022/20234.662 535 121 102 392 245 377 16 220 2.328 146 82 98
2023/2024855 238 133 55 21 30 72 18 47 19 47 84 91
2024/20253.476 460 120 432 92 544 143 60 258 306 114 431 516
2025/202611.669 455 1.664 3.317 926 3.192 2.115 0 0 0 0 0 0
Totale 26.848